Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01291004 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives
A Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 206
- Enrollment target
NCT01291004 is a Phase 1 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 206 participants.
The verdict
NCT01291004, a Phase 1 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 206 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the impact of a 28-day oral contraceptive compared to two 28-day oral contraceptive regimens containing different synthetic progestins on ovarian follicular activity and hormone levels in healthy women.
Interventions
- DRUG Desogestrel/ethinyl estradiol and ethinyl estradiol
- DRUG 28-day drospirenone oral contraceptive
- DRUG 28-day levonorgestrel oral contraceptive
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2011-01-31 |
| Est. Completion | 2012-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01291004
The ClinicalTrials.gov registry entry for NCT01291004 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Desogestrel/ethinyl estradiol and ethinyl estradiol is the first listed.
NCT01291004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01291004 about?
NCT01291004 is a clinical study titled "A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives". This study is being conducted to evaluate the impact of a 28-day oral contraceptive compared to two 28-day oral contraceptive regimens containing different synthetic progestins on ovarian follicular activity and hormone levels in healthy women.
What is the current status of trial NCT01291004?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 206 participants. The study started on 2011-01-31. Estimated completion is 2012-03-31.
What interventions are being tested in trial NCT01291004?
The interventions under investigation include: Desogestrel/ethinyl estradiol and ethinyl estradiol (DRUG), 28-day drospirenone oral contraceptive (DRUG), 28-day levonorgestrel oral contraceptive (DRUG).
Who is sponsoring clinical trial NCT01291004?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.